解读LAG-3:揭示分子机制和临床进展
Alejandra Martínez-Pérez1,2,3, Rocío Granda-Díaz1,2,3, Candelaria Aguilar-García1,2,3
1Department of Functional Biology, Immunology, Universidad de Oviedo, Oviedo, Spain.
Biomarker research
|October 18, 2024
概括
免疫检查点封锁改变了癌症治疗. 新的针对LAG-3 (淋巴细胞激活基因3) 的relatlimab抗体提供了第三种选择,扩大了固体瘤的免疫疗法组合.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症治疗 癌症治疗
背景情况:
- 免疫检查点封锁已经彻底改变了癌症治疗,PD-1/PD-L1和CTLA-4抑制剂是关键疗法.
- 尽管取得了成功,但目前只有PD-1/PD-L1和CTLA-4向抗体被批准用于患者治疗,特别是在固体瘤中.
研究的目的:
- 提供对淋巴细胞激活基因3 (LAG-3) 的生物学进行深入的审查.
- 讨论LAG-3抑制剂在癌症治疗中的当前和未来发展.
- 突出LAG-3作为癌症免疫治疗中的第三个免疫检查点目标的重要性.
主要方法:
- 关于LAG-3的临床前和临床研究的文献综述.
- 对LAG-3在免疫调节中的生物机制的分析.
- 审查目前的治疗策略和正在进行的临床试验,涉及LAG-3抑制剂.
主要成果:
- 最近批准relatlimab,一个阻断LAG-3的抗体,标志着一个重要的里程碑,引入第三个主要的免疫检查点目标.
- LAG-3在免疫反应中起着复杂的作用,其抑制为新型组合疗法提供了潜力.
- 雷拉利马布的批准为改善各种癌症治疗结果开辟了新的途径.
结论:
- 对LAG-3抑制剂的开发代表了癌症免疫疗法的重大进展.
- 了解LAG-3的复杂生物学是优化其治疗潜力的关键.
- 拉特利马布 (relatlimab) 为例的LAG-3封锁,有望扩大治疗选择并改善瘤学患者的治疗结果.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.2K
10:21Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
9.9K
相关概念视频
02:28Leaky Scanning
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:17Introduction to Language of Pathophysiology ll
This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...